Time-dependent nephrotoxicity associated with daily administration of cisplatin in Mice

Journal of Pharmacy and Pharmacology

Volumn 52, Issue 12, 2000, Pages 1499-1504

  To, H ^a,b   Kikuchi, A ^a   Tsuruoka, S ^a   Sugimoto, K ^a   Fujimura, A ^a   Higuchi, S ^b   Kayama, F ^a   Hara, K ^c   Matsuno, K ^c   Kobayashi, E ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG TISSUE LEVEL; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PHARMACODYNAMICS;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD UREA NITROGEN; BODY WEIGHT; CIRCADIAN RHYTHM; CISPLATIN; CREATININE; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-6; KIDNEY; KIDNEY DISEASES; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, INBRED BALB C; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 17744399916     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357001777711     Document Type: Article

References (21)

1. Diurnal uptake of circulating interleukin-1 alpha by brain, spinal cord, testis and muscle
2. Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer
3. Lead enhanced lipopolysaccharide and tumor necrosis factor liver injury
4. Circadian timing of cancer chemotherapy
5. Circadian stage dependence of cis-diamminediedichloroplatinum lethal toxicity in rats
6. Cadmium-induced renal damage and proinflammatory cytokines: Possible role of IL-6 in tubular epithelial cell regeneration
7. Role of tumor necrosis factor-α in cadmium-induced hepatotoxicity
8. Comparison of cisplatin-induced nephrotoxicity between dosing-time and dosing-schedule in rats
9. Single agent versus combination chemotherapy in recurrent cervical cancer
10. Circadian rhythm of soluble interleukin-2 receptor in healthy individuals
11. Reduction of cisdiamminediedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing
12. Cisplatin urinary pharmacokinetics and nephrotoxicity: A common circadian mechanism
13. Chemotherapy of advanced ovarian cancer with 4′-O-tetrahydropyranyl doxorubicin and cisplatin: A randomized phase II trial with an evaluation of circadian timing and dose-intensity
14. Plasma levels and organ distribution of platinum in the rat, dog and dogfish shark following single intravenous administration of cis-dichlorodiammineplatinum (II)
15. Cisplatin nephrotoxicity: Role of filtration and tubular transport of cisplatin in isolated perfused kidney
16. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to stage I/II patients and superior survival to other stage III patients
17. Cisplatin (cis-diamminedichloroplatinum II)
18. Combination of consecutive low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma
19. Circadian rhythm of leucocytes and lymphocyte subsets and its possible correlation with the function of the autonomic nervous system
20. Methods of reduction of cisplatin nephrotoxicity
21. Mechanism of cisplatin nephrotoxicity